Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.55 USD

197.55
4,713,450

+1.18 (0.60%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $197.40 -0.15 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat

by Zacks Equity Research

Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.

    Arpita Dutt headshot

    Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote

    by Arpita Dutt

    Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.

      Arpita Dutt headshot

      Key FDA Events to Watch Out for in Aug 2017

      by Arpita Dutt

      Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

        AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

        by Zacks Equity Research

        AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

          Arpita Dutt headshot

          4 Drug Stocks in Focus this World Hepatitis Day

          by Arpita Dutt

          Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

            AbbVie (ABBV) Tops Q2 Earnings and Revenue

            by Zacks Equity Research

            AbbVie's (ABBV) second-quarter 2017 earnings surpassed estimates with revenue marginally beating the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure

              Jeffrey Hymen headshot

              Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV

              by Jeffrey Hymen

              The Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.

                Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

                by Zacks Equity Research

                Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

                  Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

                  by Zacks Equity Research

                  Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

                    Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

                    by Zacks Equity Research

                    Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

                      Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

                      by Zacks Equity Research

                      Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                        Sweta Killa headshot

                        Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

                        by Sweta Killa

                        Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

                          AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

                          by Zacks Equity Research

                          AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

                            Is Gilead (GILD) Poised for a Beat This Earnings Season?

                            by Zacks Equity Research

                            Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

                              Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

                              by Zacks Equity Research

                              Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

                                Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

                                by Zacks Equity Research

                                At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

                                  Perrigo Company Gets FDA Approval for Generic Topical Gel

                                  by Zacks Equity Research

                                  Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                                    Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

                                    by Zacks Equity Research

                                    Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

                                      J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                                      by Zacks Equity Research

                                      Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                                        The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                                        by Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                                          Can Novartis (NVS) Spring a Surprise This Earnings Season?

                                          by Zacks Equity Research

                                          Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                                            Mark Vickery headshot

                                            Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                                            by Mark Vickery

                                            Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                                              Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                                              by Zacks Equity Research

                                              Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                                                Sweta Killa headshot

                                                IPO Market Back On Track: ETFs to Tap

                                                by Sweta Killa

                                                After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

                                                  Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                                                  by Zacks Equity Research

                                                  Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.